Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding
nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely …

Cardiovascular diseases like hypertension, hyperlipidemia, diabetes mellitus and obesity
are the important predictors of erectile dysfunction (ED). Endothelial dysfunction is proposed …

Widely distributed throughout the body, cyclic nucleotide phosphodiesterases (PDEs) are
functionally heterogeneous enzymes with potential roles in a number of physiological …

Background: Phosphodiesterase 5 inhibitors (PDE5-Is) sildenafil, vardenafil, tadalafil and
the recently approved avanafil represent the first-line choice for both on-demand and …

With three effective and safe phosphodiesterase type 5 (PDE5) inhibitors, the clinician now
has multiple choices in the treatment of patients who have erectile dysfunction of all …

Introduction Erectile dysfunction (ED) is reported in a high percentage of patients with
central neurological disorders (CND). Aim An up-to-date review on oral phosphodiesterase …

Phosphodiesterase (PDE) enzymes are widely distributed throughout the body, having
numerous effects and functions. The PDE type 5 (PDE5) inhibitors are widely used to treat …

Phosphodiesterase type 5 (PDE5) is a cyclic GMP (cGMP) specific protein. It hydrolyzes the
phosphodiesterase linkage and catalyzes the conversion of cGMP to 5'GMP, which controls …

Abstract Phosphodiesterase type 5 (PDE 5) is the major cGMP hydrolyzing enzyme in penile
corpus cavernosum and is an important regulator of nitric oxide-mediated smooth muscle …

To date, benign diseases of the male and female lower urinary and genital tract, such as
erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to …